Clinical Trial Detail

NCT ID NCT02601937
Title A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Epizyme, Inc.
Indications

kidney rhabdoid cancer

rhabdoid cancer

myoepithelial carcinoma

collecting duct carcinoma

extraskeletal myxoid chondrosarcoma

atypical teratoid rhabdoid tumor

epithelioid sarcoma

epithelioid malignant peripheral nerve sheath tumor

synovial sarcoma

Therapies

Tazemetostat

Age Groups: child adult

Additional content available in CKB BOOST